Products
We provide culture media and culture bags required for NK cell culture.
Cellex Corporation / Since 2004
Changing the future from the cell.
Cellex Corporation supports medical institutions, CPCs, and research institutions in establishing cell culture systems through products, technologies, and quality management support specialized in NK cell culture.
2004
Accumulated expertise in cell culture technology over more than 22 years.
CLINICAL&
PATENT Continuous technical improvements based on clinical practice by the inventor.
PATENT Continuous technical improvements based on clinical practice by the inventor.
30,000+Cases
Practical know-how based on clinical application at New City Osaki Clinic.
News
News
ACTO 2026 Annual Meeting Platinum Sponsor Announcement
An announcement regarding the ACTO ASPI Annual Meeting scheduled for August 26-28, 2026 in Jakarta.
Read moreAbout Cellex
A Japanese biotechnology company focused on NK cell culture
Founded in 2004, Cellex Corporation supports domestic and international partners through NK cell culture technology R&D, culture product supply and the development of standardized culture management systems.
Three Pillars
Cellex strengths
Technology
We provide an NK cell expansion culture system based on the patented technology of Cellex.
Clinical Feedback
We reflect the results of clinical application in product improvements and technology updates.
Technology Platform
Dedicated Products. Standardized Culture.
Cellex NK cell culture technology combines dedicated culture products with standardized operating procedures to support stable NK cell culture process development.
High ExpansionThrough culture using 30mL of peripheral blood, we aim to obtain over 10 billion immune cells and support efficient cell expansion.
High ActivityCulture conditions are optimized to help maintain post-culture cell activity.
Simplified ProcessSimplifies complex operations and supports process stabilization.
Standardized ManagementSOPs, record templates and training support reproducibility and traceability.
Quality Management
Cellex recommends setting key control items in the culture process, including cell count, viability, NK cell ratio, sterility testing, endotoxin testing, mycoplasma testing and culture records.
Product Series
Product lineup for NK cell culture
Cellex supports induction, expansion and culture management by combining NK cell expansion medium, culture bags and initial culture bags.
Culture Medium
Cellex NKGM-1
A medium designed for NK cell expansion culture. In combination with the Cellex culture system, it supports stable NK cell culture.
200ml / 800ml / 1000ml
Culture Bag
Cellex NKGM-Bag
A culture container used in the NK cell expansion culture process. Sterile packaging and 1L capacity support standardized operations.
Sterile package / 1L capacity
Initial Culture
NK Culture Initial Bag Ver.2.1
A culture bag used in the initial induction stage of NK cell culture, supporting stabilization and improved success rates in the initial culture process.
For initial induction stageSolutions
Implementation support for medical institutions, CPCs and research organizations
Cellex helps facilities build culture systems emphasizing safety, quality and reproducibility.
Culture products
Products supporting the NK cell culture process, including NKGM-1, NKGM-Bag and NK Culture Initial Bag Ver.2.1.
Technology implementation
Support for building NK cell culture processes based on the Cellex culture system.
SOP and documents
Support for SOPs, batch records, QC records, environmental monitoring records and training records.
Training
Video, online and on-site training for culture operations, quality management, product usage and deviation response.
Quality management
Support for setting control items such as cell count, viability, NK cell ratio, sterility testing, endotoxin testing, mycoplasma testing and records.
Intellectual Property
Intellectual property related to NK cell activation, expansion and cell manufacturing
Cellex has built intellectual property related to NK cell activation, expansion and cell manufacturing. These patents form a foundation for process stability, reproducibility and technology transfer.
- JP Patent: NK cell activation method, NK cell expansion method, cell manufacturing method and mononuclear cells containing NK cells
- JP Patent: Cancer onset inhibitor, antibody production enhancing agent and hepatitis therapeutic agent
- JP Patent: NK cell activation method, NK cell expansion method, cell manufacturing method and mononuclear cells containing NK cells
- US Patent: Cancer inhibiting agent, antibody production enhancing agent, and therapeutic agent for hepatitis
- US Patent: Immunotherapy for Pancreatic Cancer
Partnership
Business partnerships
Medical Institutions
- New City Osaki Clinic
- A specialized cancer treatment institution providing immunotherapy, including high-activity NK cell therapy.
- Osaki New City TOC Building 2F, 1-6-1 Osaki, Shinagawa-ku, Tokyo 141-0032 / TEL: 03-5437-3170
- Fujita Clinic
- 6-4-10 Himonya, Meguro-ku, Tokyo 152-0003 / TEL: 03-3712-6731
Partner Companies
- Medeze Group Public Company Limited (Thailand)
- A Thai biotechnology company focused on stem cell banking, testing, separation, culture, storage and immune cell function testing.
- Hebe Bioscience (Beijing) Cell Technology Co., Ltd
- A Beijing-based biotechnology company engaged in cell technology R&D and applications, medical research, health consulting and related technical services.
Contact
Contact Cellex
For product implementation, technical support, SOP documents or training, please contact Cellex Corporation.
03-6865-8797
ask@cellex-inc.jp
2-19-23 Kanda-Sudacho, Daiwa Akihabara Building 2F, Chiyoda-ku, Tokyo 101-0041, Japan